Search Results
Ospedale Policlinico San Martino IRCCS, Genova, Italy
Search for other papers by Federica Grillo in
Google Scholar
PubMed
Search for other papers by Tullio Florio in
Google Scholar
PubMed
Search for other papers by Francesco Ferraù in
Google Scholar
PubMed
Search for other papers by Elda Kara in
Google Scholar
PubMed
Search for other papers by Giuseppe Fanciulli in
Google Scholar
PubMed
Search for other papers by Antongiulio Faggiano in
Google Scholar
PubMed
Search for other papers by Annamaria Colao in
Google Scholar
PubMed
Search for other papers by NIKE Group in
Google Scholar
PubMed
metastatic gastroenteropancreatic neuroendocrine tumors ClinicalTrials.gov: Nbib1994213 II Advanced or metastatic gastroenteropancreatic neuroendocrine tumors Famitinib orally 25 mg once daily ORR (Time Frame: 12 weeks) 63 2017, November
Search for other papers by Murali Kesavan in
Google Scholar
PubMed
Search for other papers by Piyush Grover in
Google Scholar
PubMed
Search for other papers by Wei-sen Lam in
Google Scholar
PubMed
Search for other papers by Phillip G Claringbold in
Google Scholar
PubMed
Search for other papers by J Harvey Turner in
Google Scholar
PubMed
Introduction The last decade has seen significant advances in gastroenteropancreatic neuroendocrine tumor (GEPNET) therapy ( Hirmas et al. 2018 , Herrera-Martinez et al. 2019 ). The phase III NETTER1 study established lutetium-177-DOTA
Search for other papers by Julien Hadoux in
Google Scholar
PubMed
Search for other papers by Thomas Walter in
Google Scholar
PubMed
Search for other papers by Christina Kanaan in
Google Scholar
PubMed
Search for other papers by Ségolène Hescot in
Google Scholar
PubMed
Search for other papers by Vincent Hautefeuille in
Google Scholar
PubMed
Search for other papers by Marine Perrier in
Google Scholar
PubMed
Laboratoire GReD, Université Clermont Auvergne, Clermont-Ferrand, France
Search for other papers by Igor Tauveron in
Google Scholar
PubMed
Search for other papers by Sandrine Laboureau in
Google Scholar
PubMed
Search for other papers by Christine Do Cao in
Google Scholar
PubMed
Search for other papers by Caroline Petorin in
Google Scholar
PubMed
Search for other papers by Odile Blanchet in
Google Scholar
PubMed
Search for other papers by Matthieu Faron in
Google Scholar
PubMed
Search for other papers by Emmanuelle Leteurtre in
Google Scholar
PubMed
Search for other papers by Marie-Christine Rousselet in
Google Scholar
PubMed
Search for other papers by Juliette Joubert Zakeyh in
Google Scholar
PubMed
Search for other papers by Aude Marchal in
Google Scholar
PubMed
Search for other papers by Denis Chatelain in
Google Scholar
PubMed
Search for other papers by Clément Beaulaton in
Google Scholar
PubMed
Search for other papers by Valérie Hervieu in
Google Scholar
PubMed
Search for other papers by Catherine Lombard-Bohas in
Google Scholar
PubMed
Faculté de Médecine, Université Paris Saclay, Le Kremlin-Bicêtre, France
Search for other papers by Michel Ducreux in
Google Scholar
PubMed
Faculté de Médecine, Université Paris Saclay, Le Kremlin-Bicêtre, France
Search for other papers by Jean-Yves Scoazec in
Google Scholar
PubMed
Search for other papers by Eric Baudin in
Google Scholar
PubMed
Search for other papers by the Groupe d’Etude des Tumeurs Endocrines (GTE) in
Google Scholar
PubMed
Search for other papers by the ENDOCAN-RENATEN network in
Google Scholar
PubMed
2 . There were 48 females and 73 males. The median age was 61 (range: 22–88). Primary was of gastroenteropancreatic (GEP), thoracic, unknown (UK) or other origin in 36%, 39%, 12%, and 13% of the cases, respectively. The 44 GEP primaries were located
Search for other papers by Fritz-Line Vélayoudom-Céphise in
Google Scholar
PubMed
Search for other papers by Pierre Duvillard in
Google Scholar
PubMed
Search for other papers by Lydia Foucan in
Google Scholar
PubMed
Search for other papers by Julien Hadoux in
Google Scholar
PubMed
Search for other papers by Cecile N Chougnet in
Google Scholar
PubMed
Search for other papers by Sophie Leboulleux in
Google Scholar
PubMed
Search for other papers by David Malka in
Google Scholar
PubMed
Departments of Nuclear Medicine and Endocrine Oncology, Pathology, Department of Biostatistics and Epidemiology, Departments of Gastroenterology, Thoracic Oncology, Digestive Surgery, Medical Imaging, Faculté de Médecine Paris Sud, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif Cedex, France
Search for other papers by Joël Guigay in
Google Scholar
PubMed
Search for other papers by Diane Goere in
Google Scholar
PubMed
Search for other papers by Thierry Debaere in
Google Scholar
PubMed
Search for other papers by Caroline Caramella in
Google Scholar
PubMed
Search for other papers by Martin Schlumberger in
Google Scholar
PubMed
Departments of Nuclear Medicine and Endocrine Oncology, Pathology, Department of Biostatistics and Epidemiology, Departments of Gastroenterology, Thoracic Oncology, Digestive Surgery, Medical Imaging, Faculté de Médecine Paris Sud, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif Cedex, France
Search for other papers by David Planchard in
Google Scholar
PubMed
Search for other papers by Dominique Elias in
Google Scholar
PubMed
Departments of Nuclear Medicine and Endocrine Oncology, Pathology, Department of Biostatistics and Epidemiology, Departments of Gastroenterology, Thoracic Oncology, Digestive Surgery, Medical Imaging, Faculté de Médecine Paris Sud, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif Cedex, France
Search for other papers by Michel Ducreux in
Google Scholar
PubMed
Search for other papers by Jean-Yves Scoazec in
Google Scholar
PubMed
Search for other papers by Eric Baudin in
Google Scholar
PubMed
Introduction Gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN) are rare tumors defined by the expression of specific diagnostic biomarkers ( Baudin 2007 , Modlin et al . 2008 , Yao et al . 2008 ). Their prognosis is best characterized by
Search for other papers by Jaap J M Teunissen in
Google Scholar
PubMed
Search for other papers by Dik J Kwekkeboom in
Google Scholar
PubMed
Search for other papers by R Valkema in
Google Scholar
PubMed
Departments of, Nuclear Medicine, Internal Medicine, Erasmus Medical Centre, Rotterdam, The Netherlands
Search for other papers by Eric P Krenning in
Google Scholar
PubMed
gastroenteropancreatic neuroendocrine tumours (GEP-NETs). In the last decade, with the increasing use of positron emission tomography (PET) imaging, somatostatin analogues have been labelled with various positron-emitting isotopes, such as Gallium-68 ( 68 Ga) and Copper
Search for other papers by James C Yao in
Google Scholar
PubMed
Search for other papers by Jonathan Strosberg in
Google Scholar
PubMed
Search for other papers by Nicola Fazio in
Google Scholar
PubMed
Search for other papers by Marianne E Pavel in
Google Scholar
PubMed
Search for other papers by Emily Bergsland in
Google Scholar
PubMed
Search for other papers by Philippe Ruszniewski in
Google Scholar
PubMed
Search for other papers by Daniel M Halperin in
Google Scholar
PubMed
Search for other papers by Daneng Li in
Google Scholar
PubMed
Search for other papers by Salvatore Tafuto in
Google Scholar
PubMed
Search for other papers by Nitya Raj in
Google Scholar
PubMed
Search for other papers by Davide Campana in
Google Scholar
PubMed
Search for other papers by Susumu Hijioka in
Google Scholar
PubMed
Search for other papers by Markus Raderer in
Google Scholar
PubMed
Search for other papers by Rosine Guimbaud in
Google Scholar
PubMed
Search for other papers by Pablo Gajate in
Google Scholar
PubMed
Search for other papers by Sara Pusceddu in
Google Scholar
PubMed
Search for other papers by Albert Reising in
Google Scholar
PubMed
Search for other papers by Evgeny Degtyarev in
Google Scholar
PubMed
Search for other papers by Mark Shilkrut in
Google Scholar
PubMed
Search for other papers by Simantini Eddy in
Google Scholar
PubMed
Search for other papers by Simron Singh in
Google Scholar
PubMed
or thoracic origin, or metastatic poorly differentiated gastroenteropancreatic NEC (GEP-NEC). Patients were required to have received prior treatment for advanced disease, have radiological documentation of disease progression (NET: based on scans
Search for other papers by J Hadoux in
Google Scholar
PubMed
Search for other papers by D Malka in
Google Scholar
PubMed
Search for other papers by D Planchard in
Google Scholar
PubMed
Search for other papers by J Y Scoazec in
Google Scholar
PubMed
Search for other papers by C Caramella in
Google Scholar
PubMed
Search for other papers by J Guigay in
Google Scholar
PubMed
Search for other papers by V Boige in
Google Scholar
PubMed
Search for other papers by S Leboulleux in
Google Scholar
PubMed
Search for other papers by P Burtin in
Google Scholar
PubMed
Search for other papers by A Berdelou in
Google Scholar
PubMed
Search for other papers by Y Loriot in
Google Scholar
PubMed
Search for other papers by P Duvillard in
Google Scholar
PubMed
Search for other papers by C N Chougnet in
Google Scholar
PubMed
Search for other papers by D Déandréis in
Google Scholar
PubMed
Search for other papers by M Schlumberger in
Google Scholar
PubMed
Departments of Nuclear Medicine and Endocrine Tumors, Digestive Oncology, Medical Oncology (Thoracic Group), Pathology, Radiology, Centre Antoine Lacassagne, Department of Urologic Oncology, Department of Endocrinology, Department of Biostatistics and Epidemiology, Faculté de Médecine, Gustave Roussy, 114 Rue Edouard Vaillant, F-94800 Villejuif Cedex, France
Search for other papers by I Borget in
Google Scholar
PubMed
Departments of Nuclear Medicine and Endocrine Tumors, Digestive Oncology, Medical Oncology (Thoracic Group), Pathology, Radiology, Centre Antoine Lacassagne, Department of Urologic Oncology, Department of Endocrinology, Department of Biostatistics and Epidemiology, Faculté de Médecine, Gustave Roussy, 114 Rue Edouard Vaillant, F-94800 Villejuif Cedex, France
Search for other papers by M Ducreux in
Google Scholar
PubMed
Search for other papers by E Baudin in
Google Scholar
PubMed
subcategories Large cell 12 (60%) Small cell 7 (35%) Unknown 1 (5%) Primary Gastroenteropancreatic 12 (60%) Lung and thymus 4 (20%) Unknown 3 (15%) Bladder 1 (5%) Functioning tumor 1 (5%) Ki67 (%) <55 6 (30%) >55 12 (60%) Unknown 2 (10%) Stage
Search for other papers by S Scigliano in
Google Scholar
PubMed
Search for other papers by R Lebtahi in
Google Scholar
PubMed
Search for other papers by F Maire in
Google Scholar
PubMed
Search for other papers by J L Stievenart in
Google Scholar
PubMed
Search for other papers by R Kianmanesh in
Google Scholar
PubMed
Search for other papers by A Sauvanet in
Google Scholar
PubMed
Search for other papers by M P Vullierme in
Google Scholar
PubMed
Search for other papers by A Couvelard in
Google Scholar
PubMed
Search for other papers by J Belghiti in
Google Scholar
PubMed
Search for other papers by P Ruszniewski in
Google Scholar
PubMed
Search for other papers by D Le Guludec in
Google Scholar
PubMed
Introduction Among patients with gastroenteropancreatic neuroendocrine tumors (GEPNET), 30–80% present with synchronous or metachronous liver metastases ( Moertel 1987 , Mignon 2000 ). The presence and extent of hepatic metastases are the most
Department of Clinical Research, University of Basel, Basel, Switzerland
Search for other papers by Julia Beck in
Google Scholar
PubMed
Search for other papers by Alexander Siebenhüner in
Google Scholar
PubMed
Division of Nuclear Medicine, University Hospital Basel, Basel, Switzerland
Search for other papers by Damian Wild in
Google Scholar
PubMed
Department of Clinical Research, University of Basel, Basel, Switzerland
Search for other papers by Emanuel Christ in
Google Scholar
PubMed
Department of Clinical Research, University of Basel, Basel, Switzerland
Search for other papers by Julie Refardt in
Google Scholar
PubMed
.0589 ) Fraenkel M Kim M Faggiano A De Herder WW Valk GD & Knowledge NETwork 2014 Incidence of gastroenteropancreatic neuroendocrine tumours: a systematic review of the literature . Endocrine-Related Cancer 21 R153 – R163 . ( https://doi.org/10
Search for other papers by Nora Sahnane in
Google Scholar
PubMed
Search for other papers by Daniela Furlan in
Google Scholar
PubMed
Search for other papers by Matilde Monti in
Google Scholar
PubMed
Search for other papers by Chiara Romualdi in
Google Scholar
PubMed
Search for other papers by Alessandro Vanoli in
Google Scholar
PubMed
Search for other papers by Emanuela Vicari in
Google Scholar
PubMed
Search for other papers by Enrico Solcia in
Google Scholar
PubMed
Search for other papers by Carlo Capella in
Google Scholar
PubMed
Search for other papers by Fausto Sessa in
Google Scholar
PubMed
Search for other papers by Stefano La Rosa in
Google Scholar
PubMed
Introduction High-grade (or poorly differentiated) gastroenteropancreatic (GEP) neuroendocrine carcinomas (NECs) are aggressive cancers with a high propensity for distant metastases. Like the more frequent pulmonary counterparts, they have